Trial reportTrials2011
Prevention of hypertension in patients with pre-hypertension: protocol for the PREVER-prevention trial.
Trial report in Trials, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00970931 (Prevention of Hypertension in Patients With Pre-hypertension), which is not on this map. Cited by 16 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevention of Hypertension in Patients With Pre-hypertension: PREVER-prevention Study
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Pharmacotherapy for hypertension in adults 60 years or older.The Cochrane database of systematic reviews · 2019Pooled it
- First-line drugs for hypertension.The Cochrane database of systematic reviews · 2018Pooled it
- Pharmacotherapy for hypertension in adults aged 18 to 59 years.The Cochrane database of systematic reviews · 2017Pooled it
- Pooled it
- Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER-Prevention Randomized Clinical Trial.Journal of the American Heart Association · 2016Trial
- Epithelial sodium channel inhibition by amiloride on blood pressure and cardiovascular disease risk in young prehypertensives.Journal of clinical hypertension (Greenwich, Conn.) · 2014Trial
- Article
- Preventing the progression of prehypertension to hypertension: role of antihypertensives.Current hypertension reports · 2015Review
- Prehypertension: Underlying pathology and therapeutic options.World journal of cardiology · 2014Review
- Regarding hypertension treatment are we following worldwide tendencies?Arquivos brasileiros de cardiologia · 2014Article
- Blood pressure targets in the treatment of high blood pressure: a reappraisal of the J-shaped phenomenon.Journal of human hypertension · 2014Review
- I Brazilian position paper on prehypertension, white coat hypertension and masked hypertension: diagnosis and management.Arquivos brasileiros de cardiologia · 2014Article
- Pre-hypertension: rationale for pharmacotherapy.Current hypertension reports · 2013Review
- Cardiovascular epidemiology: the legacy of sound national and international studies.Arquivos brasileiros de cardiologia · 2013Article
- Predicting the risk of incident hypertension in a Korean middle-aged population: Korean genome and epidemiology study.Journal of clinical hypertension (Greenwich, Conn.) · 2013Article
- Reply to Visit-to-visit blood pressure variation: time to reanalyze all the data from the TROPHY study.Journal of clinical hypertension (Greenwich, Conn.) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 20 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBlood pressure (BP) within pre-hypertensive levels confers higher cardiovascular risk and is an intermediate stage for full hypertension, which develops in an annual rate of 7 out of 100 individuals with 40 to 50 years of age. Non-drug interventions to prevent hypertension have had low effectiveness. In individuals with previous cardiovascular disease or diabetes, the use of BP-lowering agents reduces the incidence of major cardiovascular events. In the absence of higher baseline risk, the use of BP agents reduces the incidence of hypertension. The PREVER-prevention trial aims to investigate the efficacy, safety and feasibility of a population-based intervention to prevent the incidence of hypertension and the development of target-organ damage.
methodsThis is a randomized, double-blind, placebo-controlled clinical trial, with participants aged 30 to 70 years, with pre-hypertension. The trial arms will be chlorthalidone 12.5 mg plus amiloride 2.5 mg or identical placebo. The primary outcomes will be the incidence of hypertension, adverse events and development or worsening of microalbuminuria and of left ventricular hypertrophy in the EKG. The secondary outcomes will be fatal or non-fatal cardiovascular events: myocardial infarction, stroke, heart failure, evidence of new sub-clinical atherosclerosis, and sudden death. The study will last 18 months. The sample size was calculated on the basis of an incidence of hypertension of 14% in the control group, a size effect of 40%, power of 85% and P alpha of 5%, resulting in 625 participants per group. The project was approved by the Ethics committee of each participating institution. DISCUSSION: The early use of blood pressure-lowering drugs, particularly diuretics, which act on the main mechanism of blood pressure rising with age, may prevent cardiovascular events and the incidence of hypertension in individuals with hypertension. If this intervention shows to be effective and safe in a population-based perspective, it could be the basis for an innovative public health program to prevent hypertension in Brazil.
trial registrationClinical Trials NCT00970931.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.